IGF-1: The growth factor that can age you faster

There’s a molecule in your blood that simultaneously builds your muscles, repairs your tissues — and may be accelerating your aging. Insulin-like growth factor 1 (IGF-1) is perhaps the most controversial molecule in longevity science because it does something profoundly useful (drive growth and repair) and something profoundly dangerous (fuel cancer cells and activate pro-aging pathways) — often at the same time.

People with Laron syndrome — a genetic condition that produces almost no IGF-1 — virtually never develop cancer. Meanwhile, high-protein diets that spike IGF-1 in adults aged 50–65 have been linked to a 75% increase in overall mortality and a fourfold increase in cancer-related deaths over 18 years — a finding with direct implications for extreme high-animal-protein patterns like the carnivore diet. On the other hand, IGF-1 that’s too low is associated with frailty, muscle wasting, and cognitive decline.

The question isn’t whether IGF-1 is good or bad — it’s finding the right level at the right age. This guide breaks down the science.

What you’ll learn:

• How IGF-1 works and why evolution gave us a growth factor that also ages us
• The optimal IGF-1 range for longevity (it’s not what most doctors test for)
• How to naturally modulate IGF-1 through diet, fasting, and exercise

---

What is IGF-1?

IGF-1 is a peptide hormone produced primarily in the liver in response to growth hormone (GH) stimulation. Structurally similar to insulin (hence “insulin-like”), it mediates many of growth hormone’s effects throughout the body.

Quick definition: IGF-1 is a growth-promoting peptide hormone that drives cell proliferation, muscle growth, and tissue repair — but also activates the mTOR pathway and suppresses autophagy, making it a key regulator of the tradeoff between growth and longevity.

Why IGF-1 matters for aging

IGF-1’s dual nature makes it central to one of the most fundamental principles in aging biology — the growth-longevity tradeoff:

• Growth and repair — IGF-1 stimulates muscle protein synthesis, bone growth, neuronal survival, and tissue regeneration. It’s essential during development and valuable for recovery at any age
• mTOR activation — IGF-1 is one of the primary activators of the mTOR pathway, which drives cell growth but suppresses autophagy — the cellular recycling process that clears damaged components
• Cell proliferation — IGF-1 promotes cell division and inhibits apoptosis (programmed cell death). This is useful for repair but problematic when it prevents damaged or precancerous cells from being eliminated
• Cancer connection — Elevated IGF-1 has been linked to increased risk of breast, prostate, colorectal, and lung cancers through its pro-proliferative and anti-apoptotic effects
• Insulin signaling — IGF-1 shares downstream signaling pathways with insulin, connecting it to metabolic health, insulin sensitivity, and glucose regulation. Together, these form the insulin/IGF-1 signaling pathway — the most replicated longevity mechanism in aging biology

---

The science behind IGF-1 and aging

The GH/IGF-1 axis across the lifespan

IGF-1 follows a distinct lifecycle pattern:

Age	IGF-1 levels	Biological role
Childhood	Rising rapidly	Essential for growth and development
Teens–20s	Peak levels (200–400 ng/mL)	Maximum growth, muscle development
30s–40s	Gradual decline begins	~14% decrease per decade
50s–60s	Continued decline	Growth promotion reduces, repair slows
70s+	Low levels (50–150 ng/mL)	Associated with frailty risk if too low

After age 30, growth hormone secretion drops approximately 14% per decade, and IGF-1 follows. By age 60, most people produce only a fraction of their youthful IGF-1. This decline — called “somatopause” — contributes to age-related muscle loss, bone thinning, increased body fat, and impaired recovery.

The longevity paradox: less growth, longer life

Here’s where the science gets fascinating.

Across virtually every species studied — worms, flies, mice, dogs, and likely humans — reduced GH/IGF-1 signaling is associated with extended lifespan. This is one of the most replicated findings in aging biology.

The Laron syndrome evidence: Individuals with Laron syndrome have a genetic mutation that makes their cells unresponsive to growth hormone, resulting in very low IGF-1. They are short in stature but exhibit remarkable resistance to cancer and diabetes. A 2023 review in Frontiers in Endocrinology confirmed that these individuals appear to be significantly protected from the diseases of aging despite having other metabolic abnormalities.

The mouse evidence: A 2018 study in Nature Communications showed that targeting the IGF-1 receptor even in late life improved healthspan and extended lifespan in female mice — demonstrating that the benefits of reduced IGF-1 signaling aren’t limited to youth.

The human evidence: Research from the EPIC-Heidelberg cohort found that higher IGF-1 levels were associated with increased cancer mortality. A landmark study by Valter Longo’s group found that among adults aged 50–65, those consuming high protein (which drives IGF-1) had a 75% increase in overall mortality and a 4x increase in cancer death over 18 years. The effect was virtually eliminated when the high protein came from plant sources — suggesting it’s the IGF-1 response to animal protein that matters.

The U-shaped curve: not too high, not too low

A meta-analysis of 19 studies including over 30,000 participants revealed that the relationship between IGF-1 and mortality follows a U-shaped curve: both very high and very low levels are associated with increased death risk.

IGF-1 range	Association
<100 ng/mL	Increased frailty, sarcopenia, cardiovascular risk, cognitive decline
100–160 ng/mL	Lowest all-cause mortality — the “longevity sweet spot”
>175 ng/mL	Progressively higher cancer risk, accelerated aging pathways
>200 ng/mL	Significantly elevated cancer and all-cause mortality risk

The practical implication: you want enough IGF-1 to maintain muscle, bone, and brain function — but not so much that you’re fueling cancer and suppressing autophagy.

Interested in how this connects? Read our guide on mTOR: when to turn it off to live longer for the full pathway picture.

---

7 proven ways to optimize IGF-1 for longevity

The goal is balance — maintaining IGF-1 in the protective range while avoiding chronic elevation.

1. Moderate protein intake — especially animal protein after 50

Why it works: Dietary protein — particularly animal protein — is the single strongest dietary driver of IGF-1 production. The amino acids leucine and methionine are especially potent IGF-1 stimulators. Moderating (not eliminating) protein intake in middle age appears to be one of the most powerful ways to reduce cancer risk while maintaining muscle.

How to do it:

• Ages 50–65: Consider moderating protein to 0.5–0.7 g per pound of body weight daily (1.1–1.5 g/kg), with emphasis on plant sources
• Ages 65+: Increase protein to 0.7–1.0 g per pound (1.5–2.2 g/kg) — the balance shifts because sarcopenia and frailty become greater threats than cancer
• Prioritize plant protein sources (legumes, nuts, soy) when possible — vegans have IGF-1 levels averaging 25–30% lower than omnivores
• Read our guide on how much protein you need after 40 for detailed age-specific recommendations

Expected results: Measurable IGF-1 reduction of 10–30% within 4–8 weeks of shifting toward plant-based protein sources.

2. Practice periodic fasting

Why it works: Fasting is the most powerful acute IGF-1 suppressor available. Even 24–48 hours of fasting can reduce IGF-1 by 20–40%. More importantly, fasting activates autophagy — the cellular cleanup process that IGF-1 normally suppresses.

How to do it:

• Time-restricted eating (16:8 or 18:6) provides mild daily IGF-1 modulation
• Periodic 24-hour fasts (1–2x per month) create deeper autophagy activation
• Extended fasting (48–72 hours, 1–4x per year under medical supervision) produces the most dramatic IGF-1 reduction
• Compare approaches in our guide to intermittent fasting vs caloric restriction

Expected results: 24-hour fast: ~15–20% IGF-1 reduction. 72-hour fast: ~40% reduction with significant autophagy activation. Effects are temporary — IGF-1 rebounds upon refeeding.

3. Maintain healthy body composition

Why it works: Excess body fat — particularly visceral fat — promotes insulin resistance, which alters the GH/IGF-1 axis. Obesity is associated with lower GH but can maintain or elevate IGF-1 through insulin-mediated hepatic production. The resulting metabolic environment promotes cancer growth while simultaneously reducing muscle-building signaling.

How to do it:

• Maintain body fat in the healthy range (10–20% for men, 18–28% for women)
• Focus on reducing visceral fat specifically — waist circumference is a useful proxy
• Combine caloric management with resistance training to preserve lean mass during fat loss

Expected results: Normalized GH/IGF-1 axis function within 8–12 weeks of significant body fat reduction. Improved IGF-1 sensitivity means lower levels produce the same beneficial effects.

4. Exercise strategically

Why it works: Exercise acutely raises IGF-1 (which is beneficial for muscle repair and adaptation) but chronic exercise patterns support a healthier baseline. Resistance training promotes local IGF-1 production in muscles (mechano growth factor) without necessarily elevating systemic IGF-1 to dangerous levels.

How to do it:

• Resistance training 3–4x per week stimulates local muscle IGF-1 for growth and repair
• Moderate aerobic exercise supports insulin sensitivity, which improves IGF-1 signaling efficiency
• Avoid chronic overtraining — excessive exercise elevates cortisol, which can dysregulate the GH/IGF-1 axis
• HIIT training produces beneficial acute GH/IGF-1 spikes without chronic elevation

Expected results: Maintained muscle mass with more efficient IGF-1 utilization. Lower systemic IGF-1 needed for the same anabolic effects when combined with exercise.

5. Reduce refined sugar and processed food

Why it works: Chronically elevated insulin (from high-glycemic diets) synergizes with IGF-1 to activate mTOR and promote cell proliferation. Insulin also reduces IGFBP-1 (a binding protein that keeps IGF-1 inactive), effectively increasing bioavailable IGF-1 without changing total levels.

How to do it:

• Minimize refined sugars, white flour, and ultra-processed foods
• Choose low-glycemic carbohydrates: vegetables, legumes, whole grains, berries
• Manage post-meal glucose spikes — glycation from glucose spikes compounds the damage from elevated IGF-1
• Consider monitoring glucose responses to understand your individual carbohydrate tolerance

Expected results: Improved insulin sensitivity and reduced bioavailable IGF-1 within 4–8 weeks. Reduced mTOR activation and improved autophagy capacity.

6. Prioritize sleep quality

Why it works: Growth hormone (which drives IGF-1 production) is primarily secreted during deep sleep. Healthy sleep patterns create a pulsatile GH/IGF-1 pattern — beneficial surges followed by clearance. Disrupted sleep creates chronically dysregulated GH secretion, which can paradoxically impair the healthy cycling that keeps IGF-1 in the optimal range.

How to do it:

• Target 7–8 hours with emphasis on deep sleep quality
• Maintain a consistent sleep schedule — GH secretion is circadian-dependent
• Avoid eating within 3 hours of bedtime — insulin from late meals suppresses GH secretion during sleep

Expected results: Normalized GH pulsatility and healthier IGF-1 cycling within 1–2 weeks of improved sleep habits.

7. Consider IGF-1 testing

Why it works: Unlike many longevity biomarkers, IGF-1 is easily measurable through a standard blood test. Knowing your level allows you to tailor your protein intake, fasting strategy, and exercise approach based on data rather than guesswork.

How to do it:

• Request a serum IGF-1 test from your doctor (fasting, morning draw preferred)
• Target the longevity-optimal range: 100–160 ng/mL for adults over 40
• Retest every 6–12 months to track trends
• Interpret in context: age, body composition, physical activity, and dietary protein all influence levels

Expected results: Actionable data to guide lifestyle decisions. Many people discover their IGF-1 is significantly above or below optimal, leading to targeted interventions.

The information provided does not replace professional medical advice. Consult your healthcare provider before making significant dietary changes or beginning any fasting protocol.

---

How to track and measure IGF-1-related health

While IGF-1 itself requires a blood test, several daily-trackable metrics reflect the metabolic environment that IGF-1 operates in.

Key metrics to monitor

Metric	Optimal range	What it indicates
Body fat %	10–20% (men), 18–28% (women)	Metabolic health; excess fat dysregulates the GH/IGF-1 axis
Lean body mass	Trending stable or up	Adequate anabolic signaling; declining lean mass may indicate IGF-1 too low
Exercise consistency	3–5 sessions/week	Training stimulus that maintains local IGF-1 production
Fasting glucose (if tracked)	70–100 mg/dL	Insulin sensitivity; elevated fasting glucose amplifies IGF-1’s pro-growth effects
HRV	Age-adjusted; higher is better	Overall metabolic and stress regulation; low HRV suggests systemic dysregulation

---

How SuperAge helps you monitor metabolic balance

The GH/IGF-1 axis interacts with nearly every metric SuperAge tracks. You can enter your IGF-1 value from blood work directly into the app, where it combines with your daily data to tell the story of the metabolic environment in which it operates.

Body composition tracking

SuperAge monitors your lean mass and body fat trends — the metrics most directly tied to IGF-1 balance. Losing muscle suggests IGF-1 may be too low; gaining visceral fat suggests insulin-IGF-1 synergy is driving metabolic dysfunction.

Training load and recovery

Your training load and exercise consistency data reflect whether you’re providing the mechanical stimulus that maintains healthy local IGF-1 production in muscles — without the chronic systemic elevation that comes from overtraining.

Your biological age, tracked

IGF-1 balance is one component of your broader biological aging rate. SuperAge calculates your biological age from multiple health metrics. Finding the IGF-1 sweet spot — enough for repair, not enough to fuel aging — directly contributes to a younger biological age.

---

Frequently asked questions

Is IGF-1 good or bad for you?

Both — and the answer depends on your age, current level, and health status. IGF-1 is essential for muscle maintenance, bone health, and brain function. But chronically elevated IGF-1 activates mTOR, suppresses autophagy, and promotes cancer cell growth. The optimal approach is to maintain IGF-1 in the moderate range (100–160 ng/mL) where you get repair benefits without excessive growth signaling. Think of it as a dimmer switch, not an on/off switch.

Does eating protein raise IGF-1?

Yes — dietary protein is the strongest dietary driver of IGF-1 production. Animal protein has a stronger effect than plant protein because it’s richer in the amino acids leucine and methionine, which are potent IGF-1 stimulators. A study comparing vegans to omnivores found 25–30% lower IGF-1 in vegans. This doesn’t mean you should eliminate protein — it means moderating intake and shifting toward plant sources, especially between ages 50 and 65 when cancer risk is rising fastest.

Should I get my IGF-1 tested?

If you’re over 40 and serious about longevity optimization, yes. It’s a standard, inexpensive blood test. Knowing your baseline allows you to calibrate protein intake and fasting strategy. Test fasting, in the morning, for the most accurate results. Most longevity-focused practitioners target 100–160 ng/mL for adults over 40, though optimal ranges may differ based on individual health status and goals.

How does IGF-1 relate to the mTOR pathway?

IGF-1 is one of the primary upstream activators of mTOR. When IGF-1 binds to its receptor, it triggers a signaling cascade (through PI3K and Akt) that activates mTORC1 — the master switch for cell growth. Activated mTOR promotes protein synthesis and cell proliferation while suppressing autophagy. This is why IGF-1 and mTOR are often discussed together in longevity science — they represent the growth side of the growth-longevity tradeoff.

Does fasting lower IGF-1?

Yes, dramatically. A 24-hour fast can reduce IGF-1 by 15–20%, and a 72-hour fast can reduce it by up to 40%. Fasting also activates AMPK (which inhibits mTOR) and triggers autophagy — making it arguably the most powerful single intervention for shifting the body from “growth mode” to “repair mode.” However, the reduction is temporary — IGF-1 rebounds upon refeeding. This is why periodic fasting, rather than chronic caloric restriction, may be the most practical approach.

---

Key takeaways

• IGF-1 is the growth-longevity tradeoff molecule: It builds muscle and repairs tissue but also activates mTOR, suppresses autophagy, and fuels cancer
• The optimal range is 100–160 ng/mL: Both too-high and too-low levels increase mortality (U-shaped curve)
• Dietary protein is the main driver: Animal protein raises IGF-1 more than plant protein — moderate intake and shift sources after 50
• Periodic fasting is the most powerful modulator: 24–72 hour fasts can reduce IGF-1 by 15–40% and activate autophagy
• Context matters by age: Ages 50–65 favor lower IGF-1 (cancer prevention). Ages 65+ favor adequate IGF-1 (sarcopenia and frailty prevention)

---

Start optimizing your growth-longevity balance

IGF-1 isn’t a villain — it’s a powerful tool that needs calibration. Too much in midlife fuels the diseases that kill most people. Too little in later life accelerates frailty. The art of longevity is knowing when to grow and when to repair.

Get tested. Adjust your protein intake. Fast periodically. Train consistently. And let data guide your decisions.

Ready to take control? Download SuperAge and start tracking the metrics that reflect your body’s growth-repair balance — body composition, training load, recovery, and biological age.

---

References

1. Longo, V.D. et al. (2014). Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metabolism, 19(3), 407–417.
2. Vitale, G. et al. (2019). ROLE of IGF-1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians’ Perspective. Frontiers in Endocrinology, 10, 27.
3. Guevara-Aguirre, J. et al. (2011). Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes. Science Translational Medicine, 3(70), 70ra13.
4. Xu, Y. et al. (2018). Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nature Communications, 9, 2394.
5. Narasimhan, S.D. et al. (2009). The GH/IGF-1 axis in ageing and longevity. Nature Reviews Endocrinology, 9(6), 366–376.
6. Renehan, A.G. et al. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk. The Lancet, 363(9418), 1346–1353.
7. Bi, T. et al. (2022). Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis. Aging, 14(3), 2223–2232.
8. Guevara-Aguirre, J. & Rosenbloom, A.L. (2023). Insulin-like growth factors and aging: lessons from Laron syndrome. Frontiers in Endocrinology, 14, 1291812.

---

Last updated: 2026-03-13. This article is regularly reviewed to ensure accuracy.